First-in-Class Intracellular Delivery Platform
COMED Hooks is designed to carry therapeutics inside the cell—reaching targets conventional biologics can't touch.
Validated in the lab. Advancing across pancreatic cancer, malaria and SMA.
Turning an Endogenous Biological Pathway into a Delivery Route
COMED Hooks are engineered antibody-based constructs that tether onto the body's own transport systems, carrying antibodies, proteins, peptides, enzymes, and nucleic acids directly into the cytoplasm.
Expanding
the Druggable Landscape
Our most advanced program targets KRAS G12V in pancreatic cancer—a driver with no FDA-approved targeted therapy.
Malaria and spinal muscular atrophy programs are advancing behind it, built on the same platform.
Demonstrated in the Lab, Confirmed in Living Models
Efficient, reproducible intracellular uptake confirmed via live-cell imaging and flow cytometry across multiple pancreatic cancer cell models.
Selective binding to KRAS G12V confirmed, with no measurable binding to the wild-type protein
Significant tumor growth suppression demonstrated in a living preclinical model, with favorable tolerability
Built to Solve an Unmet Medical Need
Founded in 2019 following a personal encounter with late-stage cancer, COMED Therapeutics assembled a team spanning molecular biology, genetics, pharmacokinetics, and medicine—now including a scientific advisory board with academic and industry leadership across Europe and the US, and advancing breakthrough discoveries toward clinical application.
Latest from COMED
COMED's latest scientific advances, company announcements, publications, strategic partnerships, and events shaping the future of intracellular therapeutics.
Presenting Our Pancreatic Cancer Work at CRIHM’s First Stakeholders’ Meeting
COMED presents its pancreatic cancer program at Malta’s first CRIHM Stakeholders’ Meeting, alongside researchers shaping the island’s cancer research agenda.
Malaria Program Completes Computational Design Phase, Backed by Xjenza Malta
COMED completes the computational design phase of its malaria antibody program, backed by Xjenza Malta and published in the journal Gene.
Presenting First-in-Class KRAS G12V Targeting at Pancreatic Cancer Europe’s 10th Anniversary Masterclass
Full in vivo data confirm COMED Hooks suppresses tumor growth in a pancreatic cancer model, with 100% survival and strong tolerability.
Whether you're exploring a partnership, evaluating an investment, or curious about the science—we'd like to hear from you.